Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026)

Sarepta Therapeutics has reported Gross Profit for 10 years, with the latest figure at $251.9 million in Q2 2026.

• On a quarterly basis, Gross Profit fell 45.07% year-over-year to $251.9 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 40.7% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 14.17% from the prior year.
• Gross Profit was $251.9 million for Q2 2026 at Sarepta Therapeutics, down from $622.0 million in the prior quarter.
• The five-year high for Gross Profit was $622.0 million in Q1 2026, with the low at $44.2 million in Q4 2025.
• Average Gross Profit over 5 years is $316.7 million, with a median of $273.3 million recorded in 2023.
• The largest YoY upside for Gross Profit was 67.34% in 2025 against a maximum downside of 91.59% in 2025.
• Over 5 years, Gross Profit stood at $227.6 million in 2022, then surged by 54.9% to $352.6 million in 2023, then surged by 49.21% to $526.1 million in 2024, then slumped by 91.59% to $44.2 million in 2025, then soared by 469.5% to $251.9 million in 2026.
• The last three Gross Profit figures came in at $251.9 million (Q2 2026), $622.0 million (Q1 2026), and $44.2 million (Q4 2025), per Business Quant data.